 |
|
|
| |
Pharmacokinetics of Glecaprevir/Pibrentasvir in Children With Chronic HCV Infection: Interim Analysis of Part 2 of the DORA Study
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Maureen M Jonas1, Hoi Kei Lon2, Susan Rhee2, Susan Gilmour3, Regino P Gonzalez-Peralta4, Daniel H Leung5, Simon C Ling6, Steven Lobritto7, Michael R Narkewicz8, Vishakha Sabharwal9, Antonio Del Valle-Segarra10, Jessica Wen11, Sandra Lovell2, Neha Thakre2, Ariel Porcalla2, Rakesh Tripathi2, Etienne Sokal121Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3Stollery Children's Hospital, and University of Alberta, Alberta, Canada; 4Pediatric Gastroenterology, Hepatology, and Liver Transplant, AdventHealth for Children, Orlando, Florida, United States; 5Division of Gastroenterology, Hepatology, and Nutrition, Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States; 6Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada; 7Morgan Stanley Children's Hospital of NY, Columbia University Irving Medical Center, New York, New York, United States; 8Digestive Health Institute, Children's Hospital Colorado, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics University of Colorado School of Medicine, Aurora, Colorado, United States; 9Division of Pediatrics Infectious Diseases, Department of Pediatrics Boston University Medical Center, Boston, Massachusetts, United States; 10San Jorge Children's Hospital, San Juan, Puerto Rico; 11Children's Hospital Philadelphia, Philadelphia, Pennsylvania, United States; 12Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium
|
| |
|
|
|
|
|
